培美曲塞联合重组人血管内皮抑制素注射液化疗同步精准放疗治疗晚期肺腺癌的效果  

Effect of pemetrexed combined with recombinant human endostatin injection chemotherapy and simultaneous precision radiotherapy on advanced lung adenocarcinoma

作　　者：杨哲[1] 任建[1] 张红[1] 何涛[1] YANG Zhe;REN Jian;ZHANG Hong;HE Tao(Radiotherapy Department,Baoji Central Hospital,Baoji 721008,China)

机构地区：[1]宝鸡市中心医院放射治疗科,陕西宝鸡721008

出　　处：《临床医学研究与实践》2020年第20期17-20,共4页Clinical Research and Practice

摘　　要：目的观察培美曲塞联合重组人血管内皮抑制素注射液化疗同步精准放疗治疗晚期肺腺癌的效果。方法选取本院2018年1月至2018年12月收治的82例晚期肺腺癌患者为研究对象,根据治疗方法的不同将其分为A组和B组,各41例。A组给予吉西他滨联合重组人血管内皮抑制素注射液化疗同步精准放疗,B组给予培美曲塞联合重组人血管内皮抑制素注射液化疗同步精准放疗。比较两组治疗前、后血清肿瘤标志物水平及生活质量、临床疗效、不良反应以及6、12个月生存率。结果治疗后,两组血清CEA、CA199和CA125水平均较治疗前降低,且B组低于A组(P<0.05)。两组临床疗效等级分布差异显著(P<0.05);B组的总缓解率高于A组(P<0.05)。治疗后,两组患者的QLQ-C30评分均较治疗前升高,且B组高于A组(P<0.05)。两组各项不良反应发生率比较,差异均无统计学意义(P>0.05)。B组的12个月生存率高于A组(P<0.05)。结论在晚期肺腺癌治疗中,培美曲塞联合重组人血管内皮抑制素注射液化疗同步精准放疗更具治疗优势,能够显著降低血清肿瘤标志物水平,增强临床疗效,改善患者的生活质量,提升生存率,且不会增加不良反应。Objective To observe the effect of pemetrexed combined with recombinant human endostatin injection chemotherapy and simultaneous precision radiotherapy on advanced lung adenocarcinoma.Methods Eighty-two patients with advanced lung adenocarcinoma admitted in our hospital from January 2018 to December 2018 were selected as the research objects and divided into group A and group B according to different treatment method,with 41 cases in each group.The group A was given gemcitabine combined with recombinant human endostatin injection chemotherapy and simultaneous precision radiotherapy.The group B was given pemetrexed combined with recombinant human endostatin injection chemotherapy and simultaneous precision radiotherapy.The levels of serum tumor markers and quality of life before and after treatment,clinical efficacy,adverse reactions,6-month and 12-month survival rates were compared between the two groups.Results After treatment,the levels of serum CEA,CA199 and CA125 in both groups were lower than those before treatment,and those in the group B were lower than the group A(P<0.05).There was significant difference in grade distribution of clinical efficacy between the two groups(P<0.05);the total remission rate of the group B was higher than that of the group A(P<0.05).After treatment,the QLQ-C30 scores of both groups were higher than those before treatment,and that of the group B was higher than the group A(P<0.05).There were no significant differences in the incidences of adverse reactions between the two groups(P>0.05).The 12-month survival rate of the group B was higher than that of the group A(P<0.05).Conclusion In the treatment of advanced lung adenocarcinoma,pemetrexed combined with recombinant human endostatin injection chemotherapy and simultaneous precision radiotherapy has more advantages,it can significantly reduce the levels of serum tumor markers,enhance the clinical efficacy,improve the quality of life and survival rate,and will not increase adverse reactions.

关 键 词：培美曲塞 重组人血管内皮抑制素注射液 精准放疗 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]